Immunohistochemistry for the detection of BRCA1 and BRCA2 ... - PubMed
The main concepts for the search were: ovarian neoplasms, IHC, BRCA1 and BRCA2. Results: Forty-four studies from 925 unique titles were included. A total of 4206 tumour samples were evaluated for BRCA1 and 1041 for BRCA2 expression. Twelve BRCA1 primary antibodies were used in 41 studies, and the most common was the MS110 clone (75.6%).
BRCA1 Immunohistochemistry in a Molecularly Characterized …
The IHC staining method for BRCA1 was optimized using the antibody in a variety of different conditions until one was chosen based on its ability to discriminate different staining patterns in a small group of ovarian cancers with known BRCA genotype. One whole section from each of these 43 high-grade serous ovarian carcinomas was evaluated with a commercially available monoclonal antibody ...
Immunohistochemistry for the detection of BRCA1 and BRCA2 …
The main concepts for the search were: ovarian neoplasms, IHC, BRCA1 and BRCA2. Results Forty-four studies from 925 unique titles were included. A total of 4206 tumour samples were evaluated for BRCA1 and 1041 for BRCA2 expression. Twelve BRCA1 primary antibodies were used in 41 studies, and the most common was the MS110 clone (75.6%).
BRCA1 immunohistochemistry in a molecularly characterized …
This study shows that BRCA1 IHC is well correlated with molecular events in ovarian carcinoma. Considering the high negative predictive value for germline mutations, BRCA1 IHC appears to be an effective approach to stratify patients for germline genetic testing and to detect other mechanisms of BRCA1 dysfunction in high-grade serous ovarian ...
BRCA immunohistochemistry for screening of BRCA mutation …
The association between BRCA IHC and BRCA mutation status are shown in Table 2, Table 3.BRCA1 IHC loss for detection of germline BRCA1 mutation had 66.7% sensitivity, 84.3% specificity, 28.6% positive predictive value (PPV), and 96.4% negative predictive value (NPV). BRCA2 IHC loss for detection of germline BRCA2 mutation had 50% sensitivity, 78.8% specificity, 12.5% PPV, and 96.3% NPV ().
The performance of BRCA1 immunohistochemistry for detecting …
2014年10月3日 · Tumors with abnormal BRCA1 IHC and wild-type germline testing underwent further evaluation for somatic BRCA1 mutations and promoter hypermethylation. McNemar's test was used to determine the association of BRCA1 IHC with germline BRCA1 mutations and BRCA1 loss through any mechanism. Kaplan–Meier …
The performance of BRCA1 immunohistochemistry for detecting …
BRCA1 expression can be lost by a variety of mechanisms including germline or somatic mutation and promotor hypermethylation. Given the potential importance of BRCA1 loss as a predictive and prognostic biomarker in high-grade serous ovarian cancer, we sought to evaluate the utility of BRCA1 immunohistochemistry (IHC) in screening for BRCA1 loss by germline, somatic, and epigenetic mechanisms.
BRCA locus-specific loss of heterozygosity in germline BRCA1 ... - Nature
2017年8月22日 · BRCA1 immunohistochemistry (IHC) was performed for 30 of 38 tumors associated with germline BRCA1 and 13 of 22 tumors associated with germline BRCA2 mutations.
BRCA1 protein expression and subcellular localization in primary …
2017年9月1日 · BRCA1 IHC staining was very weak in the stromal compartment in both normal breast and breast cancer tissues. Despite the weak IHC positivity and lower IHC H-scores compared with the IF staining, similar patterns of distribution and levels of expression were observed using the two methods (Fig 5D–5G).
BRCA1 immunohistochemistry in high-grade serous ovarian …
2012年5月20日 · Conclusions: BRCA1 IHC is a reproducible and inexpensive test with a high NPV for absence of a BRCA1 germline mutation. The 22 (17.7%) cases with abnormal BRCA1 IHC and wild-type BRCA1 germline status may have other mechanisms of protein loss such as promoter hypermethylation or somatic mutation and are currently being tested for these changes.